Semaglutide for MASH (Metabolic Dysfunction-associated Steatohepatitis) is poised to change the landscape of hepatology as Novo Nordisk prepares to unveil highly anticipated data at the [Read More…]
Accord BioPharma and Bio-Thera Solutions achieve a historic FDA approval for ImmGolis, the first interchangeable simponi biosimilar to reach the U.S. market.
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu achieves milestone FDA approvals in two early-stage HER2-positive breast cancer settings, reshaping curative care.
The Phase III VOLGA trial has reached its primary endpoints, proving that the Imfinzi EV bladder cancer combination delivers historic survival gains in the perioperative setting.
Discover how Wegovy for women delivers substantial weight loss and reduces the risk of migraines and depression across all menopausal stages, according to new Novo Nordisk data.
The recent Hympavzi European Commission Approval marks a milestone for the hemophilia community, introducing the first once-weekly anti-TFPI therapy for patients with inhibitors in the EU.
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
GenScript has launched the TurboCHOâ„¢ Protein Expression Kit in Boston, offering researchers the fastest path to high-titer antibodies with a proprietary transfection system and high-performing CHO cell line.
Novo Nordisk has unveiled groundbreaking clinical sub-analyses at the European Congress on Obesity (ECO) 2026, revealing that high-dose semaglutide (7.2 mg) can lead to nearly 28% weight loss in specific patient groups while preserving vital muscle health.
